Kegyes David, Gulei Diana, Drula Rares, Cenariu Diana, Tigu Bogdan, Dima Delia, Tanase Alina, Badelita Sorina, Buzoianu Anca-Dana, Ciurea Stefan, Ghiaur Gabriel, Terpos Evangelos, Ciechanover Aaron, Einsele Hermann, Tomuleasa Ciprian
Medfuture Research Center for Advanced Medicine / Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.
Blood Rev. 2023 Sep;61:101100. doi: 10.1016/j.blre.2023.101100. Epub 2023 May 27.
Multiple myeloma (MM) is a malignant plasma cell disorder accounting for around 1.8% of all neoplastic diseases. Nowadays, clinicians have a broad arsenal of drugs at their disposal for the treatment of MM, such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, CAR T-cell therapies and antibody-drug conjugates. In this paper we briefly highlight essential clinical elements relating to proteasome inhibitors, such as bortezomib, carfilzomib and ixazomib. Studies suggest that the early use of immunotherapy may improve outcomes significantly. Therefore, in our review we specifically focus on the combination therapy of proteasome inhibitors with novel immunotherapies and/or transplant. A high number of patients develop PI resistance. Thus, we also review new generation PIs, such as marizomib, oprozomib (ONX0912) and delanzomib (CEP-18770) and their combinations with immunotherapies.
多发性骨髓瘤（MM）是一种恶性浆细胞疾病，约占所有肿瘤性疾病的1.8%。如今，临床医生在治疗MM时有多种药物可供选择，如蛋白酶体抑制剂、免疫调节药物、单克隆抗体、双特异性抗体、嵌合抗原受体T细胞疗法和抗体药物偶联物。在本文中，我们简要介绍与蛋白酶体抑制剂（如硼替佐米、卡非佐米和伊沙佐米）相关的重要临床要点。研究表明，早期使用免疫疗法可能会显著改善治疗结果。因此，在我们的综述中，我们特别关注蛋白酶体抑制剂与新型免疫疗法和/或移植的联合治疗。大量患者会出现蛋白酶体抑制剂耐药。因此，我们还综述了新一代蛋白酶体抑制剂，如马立佐米、奥罗佐米（ONX0912）和德兰佐米（CEP-18770）及其与免疫疗法的联合应用。
